542 related articles for article (PubMed ID: 11135065)
1. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease.
Lager DJ; Qian Q; Bengal RJ; Ishibashi M; Torres VE
Kidney Int; 2001 Jan; 59(1):126-36. PubMed ID: 11135065
[TBL] [Abstract][Full Text] [Related]
2. Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease.
Zoja C; Corna D; Locatelli M; Rottoli D; Pezzotta A; Morigi M; Zanchi C; Buelli S; Guglielmotti A; Perico N; Remuzzi A; Remuzzi G
Nephron; 2015; 129(1):52-61. PubMed ID: 25531096
[TBL] [Abstract][Full Text] [Related]
3. Age-Related Alterations in Blood Biochemical Characterization of Hepatorenal Function in the PCK Rat: A Model of Polycystic Kidney Disease.
Shimomura Y; Brock WJ; Ito Y; Morishita K
Int J Toxicol; 2015; 34(6):479-90. PubMed ID: 26503599
[TBL] [Abstract][Full Text] [Related]
4. Polycystic kidney rat is a novel animal model of Caroli's disease associated with congenital hepatic fibrosis.
Sanzen T; Harada K; Yasoshima M; Kawamura Y; Ishibashi M; Nakanuma Y
Am J Pathol; 2001 May; 158(5):1605-12. PubMed ID: 11337358
[TBL] [Abstract][Full Text] [Related]
5. Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
Yoshihara D; Kugita M; Sasaki M; Horie S; Nakanishi K; Abe T; Aukema HM; Yamaguchi T; Nagao S
PLoS One; 2013; 8(12):e81480. PubMed ID: 24324698
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-to-mesenchymal transition in cyst lining epithelial cells in an orthologous PCK rat model of autosomal-recessive polycystic kidney disease.
Togawa H; Nakanishi K; Mukaiyama H; Hama T; Shima Y; Sako M; Miyajima M; Nozu K; Nishii K; Nagao S; Takahashi H; Iijima K; Yoshikawa N
Am J Physiol Renal Physiol; 2011 Feb; 300(2):F511-20. PubMed ID: 21084407
[TBL] [Abstract][Full Text] [Related]
7. Effect of a Vasopressin V2 Receptor Antagonist on Polycystic Kidney Disease Development in a Rat Model.
Wang X; Constans MM; Chebib FT; Torres VE; Pellegrini L
Am J Nephrol; 2019; 49(6):487-493. PubMed ID: 31117065
[TBL] [Abstract][Full Text] [Related]
8. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.
Wang X; Harris PC; Somlo S; Batlle D; Torres VE
Nephrol Dial Transplant; 2009 Feb; 24(2):526-34. PubMed ID: 18826972
[TBL] [Abstract][Full Text] [Related]
9. Autosomal-dominant polycystic kidney disease in the rat.
Cowley BD; Gudapaty S; Kraybill AL; Barash BD; Harding MA; Calvet JP; Gattone VH
Kidney Int; 1993 Mar; 43(3):522-34. PubMed ID: 8455352
[TBL] [Abstract][Full Text] [Related]
10. Murine autosomal recessive polycystic kidney disease with multiorgan involvement induced by the cpk gene.
Gattone VH; MacNaughton KA; Kraybill AL
Anat Rec; 1996 Jul; 245(3):488-99. PubMed ID: 8800407
[TBL] [Abstract][Full Text] [Related]
11. Azotemia and extrarenal manifestations in old female Han:SPRD (cy/+) rats.
Kränzlin B; Schieren G; Gretz N
Kidney Int; 1997 Apr; 51(4):1160-9. PubMed ID: 9083282
[TBL] [Abstract][Full Text] [Related]
12. Insignificant effect of secretin in rodent models of polycystic kidney and liver disease.
Wang X; Ye H; Ward CJ; Chu JY; Masyuk TV; Larusso NF; Harris PC; Chow BK; Torres VE
Am J Physiol Renal Physiol; 2012 Oct; 303(7):F1089-98. PubMed ID: 22811488
[TBL] [Abstract][Full Text] [Related]
13. Polycystic kidney disease in Sprague-Dawley rats.
Shoieb A; Shirai N
Exp Toxicol Pathol; 2015; 67(5-6):361-4. PubMed ID: 25753522
[TBL] [Abstract][Full Text] [Related]
14. Dietary n-3 polyunsaturated fatty acids or soy protein isolate did not attenuate disease progression in a female rat model of autosomal recessive polycystic kidney disease.
Maditz KH; Oldaker C; Nanda N; Benedito V; Livengood R; Tou JC
Nutr Res; 2014 Jun; 34(6):526-34. PubMed ID: 25026920
[TBL] [Abstract][Full Text] [Related]
15. Altered Expression and Function of Hepatic Transporters in a Rodent Model of Polycystic Kidney Disease.
Bezençon J; Beaudoin JJ; Ito K; Fu D; Roth SE; Brock WJ; Brouwer KLR
Drug Metab Dispos; 2019 Aug; 47(8):899-906. PubMed ID: 31160314
[TBL] [Abstract][Full Text] [Related]
16. Disease stage characterization of hepatorenal fibrocystic pathology in the PCK rat model of ARPKD.
Mason SB; Liang Y; Sinders RM; Miller CA; Eggleston-Gulyas T; Crisler-Roberts R; Harris PC; Gattone VH
Anat Rec (Hoboken); 2010 Aug; 293(8):1279-88. PubMed ID: 20665806
[TBL] [Abstract][Full Text] [Related]
17. Structural and functional analyses of liver cysts from the BALB/c-cpk mouse model of polycystic kidney disease.
Muchatuta MN; Gattone VH; Witzmann FA; Blazer-Yost BL
Exp Biol Med (Maywood); 2009 Jan; 234(1):17-27. PubMed ID: 18997107
[TBL] [Abstract][Full Text] [Related]
18. [Effect of a modified low protein and low fat diet on histologic changes and metabolism in kidneys in an experimental model of polycystic kidney disease].
Banković-Calić N; Ogbori MR; Nicman E
Srp Arh Celok Lek; 2002; 130(7-8):251-7. PubMed ID: 12585002
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of intrahepatic bile duct dilation of the polycystic kidney rat with a novel tyrosine kinase inhibitor gefitinib.
Sato Y; Harada K; Furubo S; Kizawa K; Sanzen T; Yasoshima M; Ozaki S; Isse K; Sasaki M; Nakanuma Y
Am J Pathol; 2006 Oct; 169(4):1238-50. PubMed ID: 17003482
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats.
Torres VE; Sweeney WE; Wang X; Qian Q; Harris PC; Frost P; Avner ED
Kidney Int; 2004 Nov; 66(5):1766-73. PubMed ID: 15496147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
